World Malaria Day 2009

  • Author: Health Informer
  • Filed under: Health News
  • Date: Apr 22,2009

“Working in Partnership: Innovating Medicines to Eradicate Malaria”
Panel Discussion Hosted by Medicines for Malaria Venture,
United Nations Office for Partnerships and Novartis

WHAT:
Medicines for Malaria Venture, United Nations Office for Partnerships and Novartis will host a luncheon panel, “Working in Partnership: Innovating Medicines to Eradicate Malaria,” leading up to the Second Annual World Malaria Day. The luncheon is part of a global discussion on the critical role of private-public partnerships in fostering research and development of life-saving anti-malarial medicines. The panel will also discuss how – through partnership and science – the global community can realize the Millennium Development Goal of halting and reversing the incidence of malaria by 2015 and the ultimate goal of malaria eradication.

WHO:
H.E. Dr. Augustine P. Mahiga, Ambassador Extraordinary and Plenipotentiary, Permanent Representative of Tanzania to the United Nations
H.E. Mr. Peter Mauer, Ambassador Extraordinary and Plenipotentiary, Permanent Representative of Switzerland to the United Nations
Mr. Amir Dossal, Executive Director, United Nations Office for Partnerships
Mr. Antony Kalm, Vice President Corporate Development, Medicines for Malaria Venture
Mr. Hans Rietveld, Director of Global Access and Marketing, Novartis Malaria Initiatives
Mr. Alan Court, Senior Advisor, United Nation’s Secretary General’s Envoy for Malaria

WHEN: Wednesday, April 22, 2009  1:00 p.m.

WHERE:

United Nations Delegates Dining Room, Room 6 United Nations Building 4th Floor New York

WHY:
Malaria kills up to one million people annually. The majority of malaria’s victims are children under five and pregnant women. In Africa, a child dies every 30 seconds from malaria.  Each year up to 250 million clinical cases of malaria are reported worldwide; medicines are critically needed to cure these potentially fatal infections.

Medicines for Malaria Venture, a not-for-profit public-private partnership, was established as a foundation in Switzerland in 1999. It is dedicated to reducing the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. Our vision is a world in which these innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate this terrible disease. For more information, visit www.mmv.org.


Two New Studies Examine the Potential Impact of Almonds in People with Type 2 Diabetes

Researchers from Asia, North America and Europe convened at the Experimental Biology (EB) Annual Meeting in New Orleans to present five new studies demonstrating the impact of one small nut on the body — the almond. Researchers got to the gut and heart of the matter, presenting emerging research that explores gut hormones and the gut’s role in nutrient and phytochemical absorption of almonds to examining the heart health impact of including almonds for individuals with type 2 diabetes. (1)(2)(3)(4)

The two studies examining the effect of almonds in people with type 2 diabetes explored the impact on cardiovascular risk factors. Cardiovascular disease is one of the leading causes of death for both men and women globally, but is of special concern for individuals with diabetes who are two to four times more likely to develop heart disease than their non-diabetic counterparts.(5)(6) Previous research including nine-clinical studies have found that almonds as part of a diet low in saturated fat and cholesterol can help maintain cholesterol levels and a healthy heart. The associated heart health effects of almonds, as well as low carbohydrate content (one-ounce of almonds contains 3g of net carbohydrates) has prompted researchers to further investigate the benefit of adding almonds and other nuts to the diets of individuals with diabetes.

Almonds Help People with Type 2 Diabetes Maintain a Healthy Heart(3)

Researchers from Taipei Medical University and Tufts University collaborated on new research presented at EB that examined the effects of almonds on risk factors for cardiovascular disease among 20 Chinese type 2 diabetic patients with mildly hyperlipidemia and treated with oral hypoglycemics. Researchers measured body fat, total cholesterol, LDL cholesterol, oxidative stress, blood sugar, insulin and inflammatory biomarkers. The 12-week clinical trial had subjects randomly assigned to receive either a NCEP Step II diet or the almond-based diet, which was the NCEP Step II diet that added almonds to replace 20 percent of the total calorie intake. At the end of the study researchers found that the almond diet led to a significant decrease in body fat by 1%, total cholesterol by 8%, and LDL cholesterol by 13%. Most importantly, researchers found that inclusion of almonds decreased blood glucose and insulin and inflammation. Alpha-Tocopherol or vitamin E levels in the blood increased, as well as the resistance of LDL cholesterol against oxidation, when tissues were tested in a laboratory environment. The NCEP Step II diet also improved cardiovascular risk factors. The changes, however, were not as clinically meaningful as those noted with the almond diet.

Dr. Oliver Chen, lead study author from Tufts University said, “The results of this study were very interesting, suggesting that more research needs to be conducted to evaluate the benefit of almonds on cholesterol and insulin resistance among individuals with type 2 diabetes from different populations.” He emphasized that more research will “provide us with a better understanding of how day-to-day diet, genetics and lifestyle factors may influence the overall contribution of almonds to the diet.”

Study at a Glance:

Subjects: Twenty Chinese type 2 diabetic patients with mild hyperlipidemia and treated with oral hypoglycemics.

Methods: A 12-week crossover clinical trial where subjects were randomly assigned to receive either a NCEP Step II diet or an Almond Diet. The Almond Diet was the NCEP Step II diet, except that almonds were added to replace 20 percent of the total caloric intake. Researchers measured body fat, glucose, insulin, total cholesterol, LDL cholesterol, oxidative stress and inflammatory biomarkers.

Results: Researchers found that the almond diet led to a significant decrease in body fat by 1%, total cholesterol by 8%, LDL cholesterol by 13%, blood sugar by 6.7%, and insulin by 7.9%. Changes were also noted among the inflammatory biomarkers measured, as well as the resistance of LDL against oxidation, when tissues were tested in a laboratory environment. Researchers also found an increase in alpha-tocopherol or vitamin E levels in the blood. The NCEP Step II diet also resulted in changes in cardiovascular risk factors. The changes however were not as clinically meaningful as those noted with the almond diet.

Almonds and other Nuts May Impact HbA1c levels and Risk for Cardiovascular Disease(4)

Another new study presented at EB by Dr. Cyril Kendall and funded by the International Tree Nut Council Nutrition and Research and Education Foundation examined the impact of nuts, including almonds, on not only cardiovascular disease risk factors, but also hemoglobin A1c (HbA1c) levels. HbA1c is a test used to estimate the management of blood sugar over the past two to three months. In this three month study, 117 individuals with diabetes treated with oral medication to help manage their blood sugar levels were randomly assigned to receive one of three diets, a full-dose mixed nut diet (75g), half-dose mixed nut diet (38g) and half portion of muffins or muffin diet (control). Researchers measured HbA1c levels, serum lipids, blood pressure, oxidative stress, and inflammatory biomarkers

Researchers found that the full dose mixed nut diet resulted in a significant improvement in glycemic control as indicated by a reduction in HbA1c levels (P<0.01). There was also a significant decrease in cardiovascular risk factors, total cholesterol (P<0.022) and LDL cholesterol (P<0.027), with the full dose mixed nut group compared to the control group.

Lead study author Dr. Kendall from the University of Toronto explained, “These findings build upon previous research which has found that nuts have a beneficial role in impacting serum lipid levels, and interestingly, also suggest that nuts may have value in promoting glycemic control.” While follow-up research is needed to explore the impact of nuts on blood sugar levels, this new study reinforces the many potential contributions nuts, including almonds, may have for our diets and health.

Study at a Glance:

Subjects: 120 Non-insulin dependent subjects with diabetes mellitus treated with oral hypoglycemic agents.

Methods: In the three-month parallel study subjects were randomized to receive one of the three treatment groups: 1) Full Dose Nut Diet-raw nuts, including almonds were added to the subjects usual diet based on energy intake. 2) Half-Dose Nut Diet-half-dose of nuts and half-dose of control muffin were provided according to calorie needs. 3) Control: Whole wheat muffins were matched with energy content of nuts provided.

One week diet histories were obtained and fasting blood samples were collected at baseline weeks 2, 4, 8, 10 and 12 to measure cardiovascular risk factors and glycemic control measures.

Results: There were no significant differences in HbA1c between diets, although after the full-dose nut diet there was a significant reduction from baseline in HbA1c levels (p<0.01) compared to the half-dose nut, and the muffin alone. There were significant differences between the full-dose nut group and the muffin group for total cholesterol (p=0.022) and LDL cholesterol (p=0.027).

For more information on almonds or these studies, please visit www.AlmondsAreIn.com.

The Almond Board of California administers a grower-enacted Federal Marketing Order under the supervision of the United States Department of Agriculture. Established in 1950, the Board’s charge is to promote the best quality almonds, California’s largest tree nut crop. For more information on the Almond Board of California or almonds, visit www.AlmondsAreIn.com.

(1) Berry, S., Lapsley, K., Tydeman, E., Lewis, H., Phalora, R., Rosborough, J., Picout, D., Ellis, P. Manipulation of lipid bioaccessibility influences postprandial vitamin E concentrations in healthy human subjects: implications for implications for inflammation, oxidative stress and vascular responses.

(2) Mandalari, G., Rich, G., Bisignano, G., Parker, M., Waldron, K., Wickham, M. Almond skins digestion using an in vitro dynamic gastric model: phytochemicals release and gut health.

(3) C-Y.O., Chen, J.-F., Liu, C.-M., Chen. Almonds ameliorate risk factors of cardiovascular disease in type 2 diabetes.

(4) Kendall, C., Esfahani, A.,Parker, T., Banach, M., Mitchell, S., Jenkins, D. Longer-term effects nuts on glycemic control in type 2 diabetes.

(5) World Health Organization. www.who.org

(6) American Heart Association www.aha.org

Source: Almond Board of California


Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented data today at the American Association for Cancer Research’s 100th Annual Meeting 2009 that could potentially provide a brighter future for children who suffer from a more deadly form of acute leukemia.

Yubin Ge, Ph.D., and Chengzhi Xie, Ph.D., presented a poster at the conference revealing that a combination of FDA-approved drugs works synergistically to help children with acute myeloid leukemia (AML). Dr. Ge is an Assistant Professor at the Karmanos Cancer Institute and at the Wayne State University School of Medicine’s Department of Pediatrics. Dr. Xie is a Postdoctoral Fellow with the Developmental Therapeutics Program at Karmanos Cancer Institute and Wayne State University School of Medicine. He also is a lecturer with the College of Life Science at Jilin University in Changchun, China.

AML, which originates in bone marrow, accounts for one-fourth of acute leukemia in children and is responsible for more than half of the leukemia deaths in this population. Approximately 600 children are diagnosed with AML each year, according to Dr. Ge and presently there is no effective drug treatment for those children should they relapse.

“Right now, we are at a bottleneck,” Dr. Ge said. “We really want to find a better treatment for those relapsed cases.”

Dr. Ge and fellow researchers considered drugs that are already FDA-approved to help fight AML. Resistance among patients to FDA-approved cytarabine is a major cause of treatment failure in AML. Scientists considered clofarabine, approved by the FDA in 2004, and paired it with valproic acid (VPA), typically used to treat epilepsy. They found the two drugs worked together to dramatically stimulate cell death.

“We considered an old drug for a new use,” Dr. Ge said. “It looks like the increased drug activity or synergy is not due to the transport or delivery of clofarabine, but to enhanced cell death. We were so pleased with the results.”

AML afflicts mostly adults — about 10,000 new cases each year — and strikes older children. Acute lymphoblastic leukemia usually affects children between the ages of 2 to 5 and is generally easier to treat. Treatment advancements for AML, however, have been less successful.

Dr. Ge said researchers at Karmanos discovered the synergy between VPA and clofarabine only a few months ago, though departmental research has spanned some 15 years in the field of treating childhood leukemias. The current research represents a unique partnership between Dr. Ge, his Karmanos colleagues, and Jeffrey W. Taub, M.D., a pediatric oncologist at Children’s Hospital of Michigan, also in Detroit.

Dr. Ge expects that their findings will move into the clinical phase in the next few years. St. Jude Children’s Research Hospital in Memphis, Tenn. Is now conducting its own clinical drug trial studying the combined effects of VPA and cytarabine to treat newly diagnosed AML patients 21 years old and younger.

“This is truly translational research,” Dr. Ge said. “We really want to translate what we do in the laboratory to the clinic and hopefully save more lives.”

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation’s best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer.

www.karmanos.org

Source: Barbara Ann Karmanos Cancer Institute


Identifies potential clinical trial strategies for personalized approach to cancer treatment

Systems Medicine, LLC (SM), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI), presented data from a preclinical study, which utilized RNA interference (RNAi) and bioinformatics to identify genetic markers – “contexts of vulnerability” – that enhance the anti-tumor response to the experimental drug candidate brostallicin, at the 2009 American Association for Cancer Research (AACR) annual meeting in Denver, Colorado. “Contexts of vulnerability” refers to the genetic configuration in a patient’s tumor that makes it susceptible to a specific drug thus providing the genetic rationale for targeted therapy. The study’s objective was to identify molecular determinants of brostallicin’s anti-tumor response that could guide clinical development and drug combination studies by incorporating an integrated pharmacogenomics approach. The study was conducted by SM in collaboration with the Translational Genomics Research Institute’s Pharmaceutical Genomics Division in Scottsdale, Arizona.

“This study has identified certain patient groups which might be more likely to benefit from therapy with brostallicin and have been invaluable in assisting us in identifying promising clinical development strategies for future development of this novel drug candidate,” said Jack Singer, M.D., Chief Medical Officer of CTI. “Ultimately, we believe this approach should shorten the clinical development time and increase the success rate by bringing us closer to being able to offer the right drug to the appropriate patient.”

Brostallicin is a small-molecule chemotherapeutic agent with a unique mechanism of action — it binds to the minor grooves located in the DNA double helix. To identify genes associated with cellular response to brostallicin, a high-throughput RNA interference screen was performed in selected ovarian cancer cell lines. RNA interference is a cellular process that results in the targeted knockdown of specific genes. The current screen assayed the effect of over 7,000 individual gene knockdowns, representing the “druggable” genome, on brostallicin response.

The identified genes, representing unique contexts of vulnerability to brostallicin, converged on cellular concepts relating to DNA repair and chromosome modification. These findings were further extended and confirmed in breast cancer cell lines, wherein the knockdown of specific genes involved in these concepts, mentioned above, resulted in an increased response to brostallicin.

To substantiate the brostallicin response observed in the RNAi studies, drugs that target selected genetic targets were tested for synergistic activity in combination with brostallicin. The outcome of this validation work has identified important contexts and rational drug combinations that will be critical for the clinical development of brostallicin.

To review the poster and see more detailed information about the study, please go to http://www.celltherapeutics.com/investor_updates.

Brostallicin

Brostallicin, a novel synthetic second-generation DNA minor groove binder, has shown potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma met its pre-defined activity and safety hurdles and resulted in a first-line phase II study that is currently being conducted by the European Organization for Research and Treatment of Cancer (EORTC).

Source: Cell Therapeutics, Inc.